Ranking Year:
# | Company Name | Region | Tech Topics | Total |
|---|
1 | Patent: 5 | |||
2 | Patent: 2 | |||
3 | Patent: 2 | |||
4 | Patent: 1 | |||
5 | Patent: 1 |
Top 5 New Entrants companies in PCSK9 Inhibitors
by Most Patent Filing In 5 Years in the China in 2020
The PCSK9 Inhibitors top 5 is Discovery PatSnap’ annual ranking of the top 5 Most Patent Filing In 5 Years PCSK9 Inhibitors New Entrants in the China. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2020, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
The PCSK9 inhibitors are a class of injectable drugs approved in 2015 that have been shown to dramatically lower LDL cholesterol levels -- by up to 60% in some cases -- when combined with a statin.. PCSK9 inhibitors are monoclonal antibodies (MABs), a type of biologic drug. They bind to and inactivate an enzyme in the liver called proprotein convertase subtilisin kexin 9 (PCSK9).
Page generation time:
May 17 2025